Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of d6-25-hydroxyvitamin D3 in Cystic Fibrosis
NCT03104855Phase 1Completed
- Sponsor
- University of Washington
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of d6-25-hydroxyvitamin D3 in cystic fibrosis (CF), sponsored by University of Washington. Primary endpoint: Metabolic Clearance of D6-25(OH)D3 at 8 weeks. Started Apr 2017; status: completed.
02
Drugs
d6-25-hydroxyvitamin D3
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03104855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104855.